Continuous infusion of recombinant interleukin-2 and lymphokine-activated killer cells in refractory malignancies.
Adoptive immunotherapy with recombinant interleukin-2 (rIL-2) and lymphokine-activated killer (LAK) cells has been reported to effect the regression of tumor in patients with a variety of malignancies. Responses have occurred in patients treated with high-dose bolus rIL2 as well as lower-dose continuous intravenous infusion. Ten patients who had been extensively pretreated with systemic chemotherapy with or without additional radiation therapy were treated with continuous infusion rIL2 and LAK cells. Five patients received rIL2 alone for 96-120 hours prior to leukapheresis in addition to rIL2 at the time of LAK cell infusion. Three patients received LAK cells that had been cultured for 14 days in an automated tissue culture system. No responses were seen in this ten-patient cohort. While the lack of response in these patients may be related to any one or more of several variables, patients who have been heavily pretreated may not respond as well as patients who have received little to no systemic chemotherapy.
Christiansen
N P
NP
Division of Medical Oncology, University of Minnesota Medical School, Minneapolis.
Kennedy
B J
BJ
Ochoa
A C
AC
Skubitz
K M
KM
Bach
F H
FH
D000328:Adult; D000368:Aged; D003110:Colonic Neoplasms / Q000628:therapy; D005260:Female; D006801:Humans; D007376:Interleukin-2 / Q000008:administration & dosage* / Q000009:adverse effects / Q000627:therapeutic use; D007680:Kidney Neoplasms / Q000628:therapy; D015979:Killer Cells, Lymphokine-Activated / Q000276:immunology*; D008214:Lymphocytes / Q000187:drug effects; D008297:Male; D008545:Melanoma / Q000628:therapy; D008875:Middle Aged; D009369:Neoplasms / Q000628:therapy*; D011994:Recombinant Proteins / Q000008:administration & dosage / Q000009:adverse effects / Q000627:therapeutic use
D007376:Interleukin-2; D011994:Recombinant Proteins